BioCardia
BCDA
24 hedge funds and large institutions have $5.49M invested in BioCardia in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 23 → 24 (+1)
0.13% less ownership
Funds ownership: 1.18% → 1.05% (-0.13%)
5% less capital invested
Capital invested by funds: $5.78M → $5.49M (-$292K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
55% less call options, than puts
Call options by funds: $87K | Put options by funds: $195K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$472K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$54.3K |
| 3 |
Renaissance Technologies
New York
|
+$27.1K |
| 4 |
LPL Financial
San Diego,
California
|
+$21.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$21.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$796K |
| 2 |
FM
Family Management
New York
|
-$276K |
| 3 |
VF
Virtu Financial
New York
|
-$109K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$41K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16.4K |
BCDA Hedge Fund Activity: Q1 2022 in Review
24 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q1 2022, worth a combined $5.49M — down 5.1% from $5.78M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BCDA positions and 4 closed out — a net gain of 1 holder — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $472K. The largest seller was Roumell Asset Management, cutting an estimated $796K.
- 24 institutional investors held BioCardia (BCDA) as of Q1 2022, up from 23 in Q4 2021.
- Funds reported $5.49M of BioCardia stock for Q1 2022, down 5.1% quarter-over-quarter.
- 5 funds opened new BioCardia positions in Q1 2022 and 4 closed out, a net change of +1 holder.
- The largest BioCardia buyer in Q1 2022 was Vanguard Group, an estimated $472K added.
- The largest BioCardia seller in Q1 2022 was Roumell Asset Management, an estimated $796K sold.
Based on aggregated 13F filings for Q1 2022.